Related Experiment Videos
Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism
1Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden.
Insights
Untreated growth hormone deficiency (GHD) increases mortality, primarily from cardiovascular disease. Growth hormone (GH) treatment may improve cardiovascular health and psychosocial well-being, potentially lowering this risk.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Untreated growth hormone deficiency (GHD) is linked to increased mortality in hypopituitarism patients.
- Cardiovascular disease is the primary cause of excess mortality in this population.
- Risk factors include dyslipidaemia, abdominal obesity, hypertension, and altered fibrinolysis.
Purpose of the Study:
- To investigate the cardiovascular risks associated with untreated GHD.
- To explore the potential benefits of growth hormone (GH) replacement therapy on cardiovascular health and overall mortality.
- To assess the impact of GH treatment on psychosocial well-being in patients with GHD.
Main Methods:
- Review of existing literature on GHD, hypopituitarism, and cardiovascular outcomes.
- Analysis of studies examining the effects of GH treatment on cardiovascular risk factors.
- Evaluation of data on psychosocial well-being in patients receiving GH therapy.
Main Results:
- Untreated GHD contributes significantly to cardiovascular abnormalities and increased mortality.
- GH treatment demonstrates efficacy in correcting many cardiovascular abnormalities.
- GH therapy is associated with improved psychosocial well-being, potentially reducing overall risk.
Conclusions:
- Growth hormone deficiency poses a substantial cardiovascular risk in hypopituitarism.
- Growth hormone replacement therapy is a viable strategy to mitigate cardiovascular risks and improve patient outcomes.
- Addressing both physiological and psychosocial aspects is crucial for managing patients with GHD.
Abstract:
Untreated growth hormone deficiency (GHD) might explain the increased mortality reported in patients with hypopituitarism. These statistics appear to be largely attributable to cardiovascular disease. Differences in fibrinolytic activity regulators, together with dyslipidaemias, abdominal obesity and raised blood pressure in hypopituitarism might explain this increased risk. There is growing evidence that treatment with growth hormone (GH) can rectify most of the cardiovascular abnormalities associated with GHD. The reported improved psychosocial well-being in response to GH treatment may also be important in lowering risk in this group of patients.